目的 探討芪參益氣滴丸聯(lián)合鹽酸地爾硫（艸卓）片治療穩(wěn)定型心絞痛的臨床療效。方法 選擇2020年2月—2020年9月在開(kāi)封市中心醫(yī)院治療96例穩(wěn)定型心絞痛患者，根據(jù)住院序號(hào)的奇偶性分成對(duì)照組（48例）和治療組（48例）。對(duì)照組口服鹽酸地爾硫（艸卓）片，30 mg/次，3次/d；治療組在對(duì)照組基礎(chǔ)上飯后口服芪參益氣滴丸，0.5 g/次，3次/d。兩組患者均經(jīng)4周治療。觀察兩組患者臨床療效，比較治療前后兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時(shí)間，血清內(nèi)皮細(xì)胞黏附分子1（VCAM-1）、活性氧自由基（ROS）、可溶性CD40配體（sCD40L）、轉(zhuǎn)化生長(zhǎng)因子β1（TGF-β1）、人白三烯B4（LTB4）和心肌營(yíng)養(yǎng)素1（CT-1）水平，及SAQ、Gensini和GQOLI-74評(píng)分。結(jié)果 經(jīng)治療，對(duì)照組和治療組總有效率分別為83.33%和97.92%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。經(jīng)治療，兩組心絞痛發(fā)作次數(shù)、每次持續(xù)時(shí)間均顯著減少（P<0.05），且治療組減少更明顯（P<0.05）。治療后，兩組VCAM-1、ROS、sCD40L、LTB4、CT-1水平均明顯降低，而TGF-β1明顯升高（P<0.05），且治療組這些指標(biāo)明顯好于對(duì)照組（P<0.05）。治療后，兩組患者SAQ和GQOLI-74評(píng)分顯著升高，而Gensini評(píng)分顯著降低（P<0.05），且治療組明顯好于對(duì)照組（P<0.05）。結(jié)論 芪參益氣滴丸聯(lián)合鹽酸地爾硫（艸卓）片治療穩(wěn)定型心絞痛患者可有效改善患者胸痛癥狀，提高患者生活質(zhì)量及改善冠狀動(dòng)脈受損情況，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Qishen Yiqi Pills combined with diltiazem hydrochloride in treatment of stable angina pectoris. Methods Patients (96 cases) with stable angina pectoris in Kaifeng Central Hospital from February 2020 to September 2020 were divided into control (48 cases) and treatment (48 cases) groups according to the parity of the hospitalization number. Patients in the control group were po administered with Diltiazem Hydrochloride Tablets, 30 mg/time, three times daily. Patients in the treatment group were po administered with Qishen Yiqi Pills on the basis of the control group, 0.5 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the frequency and duration of angina pectoris, and the serum levels of VCAM-1, ROS, sCD40L, LTB4, CT-1, and TGF-β1, and the scores of SAQ, Gensini, and GQOLI-74 in two groups before and after treatment were compared. Results After treatment, the clinical effective rates of the control group and the treatment group were 83.33% and 97.92%, respectively, and the difference between the two groups was statistically significant (P<0.05). After treatment, the attack times and duration of angina pectoris were significantly decreased in two groups (P<0.05), especially in the treatment group (P<0.05). After treatment, the serum levels of VCAM-1, ROS, sCD40L, LTB4, and CT-1 in two groups were significantly decreased, while TGF- β1 were significantly increased (P<0.05), and these indexes in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the SAQ and GQOLI-74 scores of the two groups were significantly increased, while the Gensini scores were significantly decreased (P<0.05), and the treatment group was significantly better than the control group (P<0.05). Conclusion Qishen Yiqi Pills combined with diltiazem hydrochloride in treatment of stable angina pectoris can effectively improve the symptoms of chest pain, improve the quality of life and improve the damage of coronary artery, which has a certain clinical application value.

R972